Literature DB >> 14563643

LPAM (alpha 4 beta 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease.

Aleksandra Petrovic1, Onder Alpdogan, Lucy M Willis, Jeffrey M Eng, Andrew S Greenberg, Barry J Kappel, Chen Liu, George J Murphy, Glenn Heller, Marcel R M van den Brink.   

Abstract

Lymphocyte Peyer patch adhesion molecule (LPAM) or alpha(4)beta(7) integrin is expressed on lymphocytes and is responsible for T-cell homing into gut-associated lymphoid tissues through its binding to mucosal addressin cell adhesion molecule (MAdCAM), which is present on high endothelial venules of mucosal lymphoid organs. We found in murine allogeneic bone marrow transplantation (BMT) models that recipients of alpha(4)beta(7)(-) donor T cells had significantly less graft-versus-host disease (GVHD) morbidity and mortality compared with recipients of alpha(4)beta(7)(+) donor T cells. A kinetic posttransplantation analysis of lymphocytes in the intestines and mesenteric lymph nodes demonstrated a delayed invasion of lower numbers of alpha(4)beta(7)(+) T cells in recipients of alpha(4)beta(7)(-) T cells compared with recipients of alpha(4)beta(7)(+) T cells. Histopathologic analysis of GVHD target organs revealed that recipients of alpha(4)beta(7)(-) T cells developed less GVHD of the intestines and liver, whereas there was no difference in cutaneous and thymic GVHD between recipients of alpha(4)beta(7)(-) or alpha(4)beta(7)(+) T cells. Finally, we found that in vivo GVT activity of alpha(4)beta(7)(-) donor T cells was preserved. We conclude that the alpha(4)beta(7) integrin is important for the invasion of alloreactive donor T cells into the gut and the subsequent development of intestinal GVHD and overall GVHD morbidity and mortality.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14563643     DOI: 10.1182/blood-2003-03-0957

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  70 in total

1.  The Role of Integrin Expressing Cells in Modulating Disease Susceptibility and Progression (January 2016).

Authors:  Aftab A Ansari; Siddappa N Byrareddy
Journal:  Int Trends Immun       Date:  2016-01

Review 2.  New and emerging therapies for acute and chronic graft versus host disease.

Authors:  LaQuisa Hill; Amin Alousi; Partow Kebriaei; Rohtesh Mehta; Katayoun Rezvani; Elizabeth Shpall
Journal:  Ther Adv Hematol       Date:  2017-11-28

3.  The triterpenoid CDDO-Me delays murine acute graft-versus-host disease with the preservation of graft-versus-tumor effects after allogeneic bone marrow transplantation.

Authors:  Minghui Li; Kai Sun; Doug Redelman; Lisbeth A Welniak; William J Murphy
Journal:  Biol Blood Marrow Transplant       Date:  2010-03-23       Impact factor: 5.742

4.  Prevention of acute graft-versus-host disease by blocking T-cell entry to secondary lymphoid organs.

Authors:  Andreas Beilhack; Stephan Schulz; Jeanette Baker; Georg F Beilhack; Ryosei Nishimura; Enosh M Baker; Gilad Landan; Edward I Herman; Eugene C Butcher; Christopher H Contag; Robert S Negrin
Journal:  Blood       Date:  2007-11-07       Impact factor: 22.113

5.  L-selectin and beta7 integrin on donor CD4 T cells are required for the early migration to host mesenteric lymph nodes and acute colitis of graft-versus-host disease.

Authors:  Suparna Dutt; Joerg Ermann; Diane Tseng; Yin Ping Liu; Tracy I George; C Garrison Fathman; Samuel Strober
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

6.  A small-molecule c-Rel inhibitor reduces alloactivation of T cells without compromising antitumor activity.

Authors:  Yusuke Shono; Andrea Z Tuckett; Samedy Ouk; Hsiou-Chi Liou; Grégoire Altan-Bonnet; Jennifer J Tsai; Jennifer E Oyler; Odette M Smith; Mallory L West; Natalie V Singer; Ekaterina Doubrovina; Dmitry Pankov; Chandresh V Undhad; George F Murphy; Cecilia Lezcano; Chen Liu; Richard J O'Reilly; Marcel R M van den Brink; Johannes L Zakrzewski
Journal:  Cancer Discov       Date:  2014-02-18       Impact factor: 39.397

7.  PKCtheta is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice.

Authors:  Javier O Valenzuela; Cristina Iclozan; Mohammad S Hossain; Martin Prlic; Emily Hopewell; Crystina C Bronk; Junmei Wang; Esteban Celis; Robert W Engelman; Bruce R Blazar; Michael J Bevan; Edmund K Waller; Xue-Zhong Yu; Amer A Beg
Journal:  J Clin Invest       Date:  2009-11-09       Impact factor: 14.808

8.  The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease.

Authors:  Il-Kang Na; Sydney X Lu; Nury L Yim; Gabrielle L Goldberg; Jennifer Tsai; Uttam Rao; Odette M Smith; Christopher G King; David Suh; Daniel Hirschhorn-Cymerman; Lia Palomba; Olaf Penack; Amanda M Holland; Robert R Jenq; Arnab Ghosh; Hien Tran; Taha Merghoub; Chen Liu; Gregory D Sempowski; Melissa Ventevogel; Nicole Beauchemin; Marcel R M van den Brink
Journal:  J Clin Invest       Date:  2009-12-01       Impact factor: 14.808

9.  Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cells.

Authors:  Britt E Anderson; Patricia A Taylor; Jennifer M McNiff; Dhanpat Jain; Anthony J Demetris; Angela Panoskaltsis-Mortari; Ann Ager; Bruce R Blazar; Warren D Shlomchik; Mark J Shlomchik
Journal:  Blood       Date:  2008-02-19       Impact factor: 22.113

10.  A critical role for the retinoic acid signaling pathway in the pathophysiology of gastrointestinal graft-versus-host disease.

Authors:  Xiao Chen; Joseph Dodge; Richard Komorowski; William R Drobyski
Journal:  Blood       Date:  2013-03-25       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.